tiprankstipranks
Trending News
More News >
Amgen (AMGN)
NASDAQ:AMGN
US Market
Advertisement

Amgen (AMGN) Stock Forecast & Price Target

Compare
6,551 Followers
See the Price Targets and Ratings of:

AMGN Analyst Ratings

Moderate Buy
23Ratings
Moderate Buy
11 Buy
11 Hold
1 Sell
Based on 23 analysts giving stock ratings to
Amgen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$326.06
▲(6.66%Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $326.06 with a high forecast of $400.00 and a low forecast of $261.00. The average price target represents a 6.66% change from the last price of $305.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"255":"$255","328":"$328","401":"$401","291.5":"$291.5","364.5":"$364.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$400.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":326.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$326.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":261,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$261.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[255,291.5,328,364.5,401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.52,298.94153846153847,307.3630769230769,315.7846153846154,324.2061538461538,332.6276923076923,341.04923076923075,349.47076923076924,357.89230769230767,366.31384615384616,374.7353846153846,383.1569230769231,391.5784615384615,{"y":400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.52,293.25384615384615,295.98769230769227,298.72153846153844,301.4553846153846,304.18923076923073,306.9230769230769,309.6569230769231,312.39076923076925,315.12461538461537,317.85846153846154,320.5923076923077,323.32615384615383,{"y":326.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.52,288.24923076923073,285.97846153846154,283.7076923076923,281.43692307692305,279.16615384615386,276.8953846153846,274.62461538461537,272.3538461538461,270.08307692307693,267.8123076923077,265.54153846153844,263.27076923076925,{"y":261,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":301.29,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":280.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$400.00Average Price Target$326.06Lowest Price Target$261.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AMGN
TipRanks AITipRanks
Not Ranked
TipRanks
$324
Buy
5.99%
Upside
Reiterated
07/02/25
Amgen's strong financial performance and positive earnings call highlight its strengths in profitability and growth potential. While technical indicators are less favorable, and high leverage poses some risk, the company's strategic investments and robust cash flow provide a solid foundation for long-term growth.
Bank of America Securities Analyst forecast on AMGN
Tim AndersonBank of America Securities
Bank of America Securities
$252$261
Sell
-14.62%
Downside
Reiterated
07/23/25
Amgen's Overvaluation and Cautious Outlook Lead to Underperform Rating
Citi
$300$305
Hold
-0.23%
Downside
Reiterated
07/23/25
Amgen price target raised to $305 from $300 at CitiAmgen price target raised to $305 from $300 at Citi
Guggenheim Analyst forecast on AMGN
Vamil DivanGuggenheim
Guggenheim
$288
Hold
-5.79%
Downside
Reiterated
07/22/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Amgen (NASDAQ: AMGN) and Cross Country Healthcare (NASDAQ: CCRN)We maintain our $288 price target and Neutral rating on AMGN shares.
Piper Sandler Analyst forecast on AMGN
David AmsellemPiper Sandler
Piper Sandler
$328
Buy
7.30%
Upside
Reiterated
07/22/25
Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
UBS
$315$326
Hold
6.64%
Upside
Reiterated
07/21/25
Amgen price target raised to $326 from $315 at UBSAmgen price target raised to $326 from $315 at UBS
Wells Fargo Analyst forecast on AMGN
Mohit BansalWells Fargo
Wells Fargo
$280
Hold
-8.40%
Downside
Reiterated
07/14/25
Amgen's Mixed Performance Signals: Hold Rating Amid Growth Opportunities and Risks
J.P. Morgan Analyst forecast on AMGN
Chris SchottJ.P. Morgan
J.P. Morgan
$300
Hold
-1.86%
Downside
Reiterated
07/14/25
J.P. Morgan Sticks to Their Hold Rating for Amgen (AMGN)
Morgan Stanley Analyst forecast on AMGN
Terence FlynnMorgan Stanley
Morgan Stanley
$330
Hold
7.95%
Upside
Reiterated
07/10/25
Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)
BMO Capital Analyst forecast on AMGN
Evan SeigermanBMO Capital
BMO Capital
$346$335
Buy
9.59%
Upside
Reiterated
07/09/25
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
Bernstein
$350
Buy
14.50%
Upside
Reiterated
07/08/25
Amgen (AMGN) Gets a Buy from Bernstein
RBC Capital Analyst forecast on AMGN
Luca IssiRBC Capital
RBC Capital
$320
Buy
4.68%
Upside
Reiterated
07/07/25
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (NASDAQ: MREO), Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)
TD Cowen Analyst forecast on AMGN
Yaron WerberTD Cowen
TD Cowen
$389
Buy
27.25%
Upside
Reiterated
06/30/25
Amgen (AMGN) Receives a Buy from TD Cowen
William Blair Analyst forecast on AMGN
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
06/30/25
Amgen's Promising Clinical Trial Results Justify Buy Rating Despite Adverse Event Concerns
Leerink Partners Analyst forecast on AMGN
David RisingerLeerink Partners
Leerink Partners
Hold
Reiterated
06/24/25
Amgen's Cautious Progress and Long-Term Strategy Justifies Hold Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AMGN
TipRanks AITipRanks
Not Ranked
TipRanks
$324
Buy
5.99%
Upside
Reiterated
07/02/25
Amgen's strong financial performance and positive earnings call highlight its strengths in profitability and growth potential. While technical indicators are less favorable, and high leverage poses some risk, the company's strategic investments and robust cash flow provide a solid foundation for long-term growth.
Bank of America Securities Analyst forecast on AMGN
Tim AndersonBank of America Securities
Bank of America Securities
$252$261
Sell
-14.62%
Downside
Reiterated
07/23/25
Amgen's Overvaluation and Cautious Outlook Lead to Underperform Rating
Citi
$300$305
Hold
-0.23%
Downside
Reiterated
07/23/25
Amgen price target raised to $305 from $300 at CitiAmgen price target raised to $305 from $300 at Citi
Guggenheim Analyst forecast on AMGN
Vamil DivanGuggenheim
Guggenheim
$288
Hold
-5.79%
Downside
Reiterated
07/22/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Amgen (NASDAQ: AMGN) and Cross Country Healthcare (NASDAQ: CCRN)We maintain our $288 price target and Neutral rating on AMGN shares.
Piper Sandler Analyst forecast on AMGN
David AmsellemPiper Sandler
Piper Sandler
$328
Buy
7.30%
Upside
Reiterated
07/22/25
Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
UBS
$315$326
Hold
6.64%
Upside
Reiterated
07/21/25
Amgen price target raised to $326 from $315 at UBSAmgen price target raised to $326 from $315 at UBS
Wells Fargo Analyst forecast on AMGN
Mohit BansalWells Fargo
Wells Fargo
$280
Hold
-8.40%
Downside
Reiterated
07/14/25
Amgen's Mixed Performance Signals: Hold Rating Amid Growth Opportunities and Risks
J.P. Morgan Analyst forecast on AMGN
Chris SchottJ.P. Morgan
J.P. Morgan
$300
Hold
-1.86%
Downside
Reiterated
07/14/25
J.P. Morgan Sticks to Their Hold Rating for Amgen (AMGN)
Morgan Stanley Analyst forecast on AMGN
Terence FlynnMorgan Stanley
Morgan Stanley
$330
Hold
7.95%
Upside
Reiterated
07/10/25
Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)
BMO Capital Analyst forecast on AMGN
Evan SeigermanBMO Capital
BMO Capital
$346$335
Buy
9.59%
Upside
Reiterated
07/09/25
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
Bernstein
$350
Buy
14.50%
Upside
Reiterated
07/08/25
Amgen (AMGN) Gets a Buy from Bernstein
RBC Capital Analyst forecast on AMGN
Luca IssiRBC Capital
RBC Capital
$320
Buy
4.68%
Upside
Reiterated
07/07/25
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (NASDAQ: MREO), Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)
TD Cowen Analyst forecast on AMGN
Yaron WerberTD Cowen
TD Cowen
$389
Buy
27.25%
Upside
Reiterated
06/30/25
Amgen (AMGN) Receives a Buy from TD Cowen
William Blair Analyst forecast on AMGN
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
06/30/25
Amgen's Promising Clinical Trial Results Justify Buy Rating Despite Adverse Event Concerns
Leerink Partners Analyst forecast on AMGN
David RisingerLeerink Partners
Leerink Partners
Hold
Reiterated
06/24/25
Amgen's Cautious Progress and Long-Term Strategy Justifies Hold Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month
xxx
Success Rate
15/29 ratings generated profit
52%
Average Return
-0.50%
assigned a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.72% of your transactions generating a profit, with an average return of -0.50% per trade.
3 Months
xxx
Success Rate
21/34 ratings generated profit
62%
Average Return
+2.34%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.76% of your transactions generating a profit, with an average return of +2.34% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
28/38 ratings generated profit
74%
Average Return
+11.93%
reiterated a buy rating 24 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +11.93% per trade.
2 Years
xxx
Success Rate
28/34 ratings generated profit
82%
Average Return
+14.24%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +14.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
29
27
27
36
35
Hold
13
16
18
27
25
Sell
3
3
4
5
5
Strong Sell
0
0
0
0
0
total
45
46
49
68
65
In the current month, AMGN has received 35 Buy Ratings, 25 Hold Ratings, and 5 Sell Ratings. AMGN average Analyst price target in the past 3 months is 326.06.
Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $5.28 with a range of $4.81 to $5.84. The previous quarter’s EPS was $4.90. AMGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.
Next quarter’s earnings estimate for AMGN is $5.28 with a range of $4.81 to $5.84. The previous quarter’s EPS was $4.90. AMGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $8.93B with a range of $8.62B to $9.32B. The previous quarter’s sales results were $8.09B. AMGN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.
Next quarter’s sales forecast for AMGN is $8.93B with a range of $8.62B to $9.32B. The previous quarter’s sales results were $8.09B. AMGN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is 326.06.
    What is AMGN’s upside potential, based on the analysts’ average price target?
    Amgen has 6.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AMGN a Buy, Sell or Hold?
          Amgen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 11 hold ratings and 1 sell ratings.
            What is Amgen’s price target?
            The average price target for Amgen is 326.06. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $400.00 ,the lowest forecast is $261.00. The average price target represents 6.66% Increase from the current price of $305.69.
              What do analysts say about Amgen?
              Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of AMGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis